Based on prior clinical data, the 'Fast Assessment of Lung Maturity at Birth' study demonstrates that measuring lung maturity biomarkers, AI can predict Respiratory Distress Syndrome (RDS) with high accuracy (91% sensitivity) moments after birth.
Objective: To analyze the therapeutic effect of pulmonary surfactant (PS) in combination with nasal continuous positive airway pressure (NCPAP) therapy on neonatal respiratory distress syndrome (NRDS).
In acute respiratory distress syndrome (ARDS), BPFs can cause incomplete lung expansion, loss of effective tidal volume and positive end expiratory pressure (PEEP), and reduced carbon dioxide elimination .
(6) In 1967, Ashbaugh et al (1) coined the now well-known term acute respiratory distress syndrome to describe a clinical syndrome characterized by "an acute onset of tachypnea, hypoxaemia, and loss of compliance after a variety of stimuli." In 1994, the American-European Consensus Conferences (AECC) on ARDS published a statement on definitions, mechanisms, relevant outcomes, and clinical trial coordination (7) that attempted to delineate and guide treatment; however, there remained some confusion due to overlapping criteria applied to the definition of ALI and ARDS, specifically in relation to hypoxia levels and imaging interpretation.